|会社名||Aquestive Therapeutics Inc （アクエスティブ・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 Aquestive Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant Sympazan and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108 and AQST-305 for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs which includes Suboxone and APL-130277 for the treatment of opioid dependence and Parkinson’s disease. アクエスティブ・セラピュ―ティクスは米国の特殊医薬品企業。主に満たされていない医療ニ―ズに焦点を当て、製品の特定や開発、商業化に従事する。同社の「PharmFilm」は既存の処方薬を直接血流に送達するプラットフォ―ム医薬製剤。医薬品フィルム、個別使用フィルム、患者・医師・介護用のフィルムなどを製造する。本社所在地はニュ―ジャ―ジ―州ウォ―レン。 Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.|
|本社所在地||30 Technology Drive Warren NJ 07059 USA|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Aquestive Therapeutics Inc revenues increased 35% to $37.3M. Net loss applicable to common stockholders increased from $8.6M to $32.4M. Revenues reflect United States segment increase of 46% to $23.2M Malaysia segment increase of 22% to $33K. Higher net loss reflects Selling General and administrative increase from $10.6M to $41.2M (expense) Research_Development increase of 18% to $12.9M (expense).|
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives 2023/01/06 13:00:00 GlobeNewswire
WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives. In addition, Aquestive’s Chief Executive Officer, Daniel Barber, and Chief Financial Officer, Ernie Toth, will host investor meetings from January 9 to 11, 2023 in San Francisco, concurrent with the 41st Annual J. P. Morgan Healthcare Conference.
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film) 2022/12/22 13:00:00 GlobeNewswire
WARREN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia 2022/11/29 13:00:00 GlobeNewswire
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray
Aquestive Therapeutics: Going All-In On AQST-109 (NASDAQ:AQST) 2022/11/29 08:18:05 Seeking Alpha
Aquestive Therapeutics has been making deals to generate cash to help develop of their epinephrine candidate, AQST-109. See why AQST stock is a Buy.
Was anything positive for Aquestive Therapeutics Inc. (AQST) stock last session? 2022/11/24 19:48:00 US Post News
Aquestive Therapeutics Inc. (NASDAQ:AQST) closed Wednesday at $0.93 per share, up from $0.90 a day earlier. While Aquestive Therapeutics Inc. has overperformed by 2.72%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST fell by -84.49%, with highs and lows ranging from $6.40 to $0.62, whereas […]
Aquestive Therapeutics Stock: FDA Stymies Libervant Launch (NASDAQ:AQST) 2022/09/05 07:43:21 Seeking Alpha
Aquestive Therapeutics shares have lost two-thirds of their value this year. Read why AQST stock is uninvestable for me at the present.
Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant 2022/09/02 17:38:55 Seeking Alpha
After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive''s Libervant. Unfortunately, the company cannot market the product.
Aquestive Therapeutics to Participate in Two Investor Conferences in September 2022/08/31 20:02:00 GlobeNewswire
WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September as follows:
AQST stock on watch after FDA tentative approval for ant-seizure drug (NASDAQ:AQST) 2022/08/31 12:25:35 Seeking Alpha
Aquestive Therapeutics (AQST), a company focused on different formulations of drugs announced Wednesday that the FDA granted tentative approval for Libervant (diazepam) Buccal Film…
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film 2022/08/31 12:00:00 GlobeNewswire
WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval for Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity ( i.e. , seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share 2021/12/06 14:30:00 Marketing Sentinel
In the last trading session, 1.14 million Aquestive Therapeutics Inc. (NASDAQ:AQST) shares changed hands as the companys beta touched 3.47. With the companys per share price at $4.84 changed hands at -$0.54 or -10.04% during last session, the market valuation stood at $216.11M. AQSTs last price was a discount, traded about -66.53% off its 52-week Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share Read More »
Squarepoint Ops LLC Makes New $79,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) 2021/11/27 10:08:44 Dakota Financial News
Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,824 shares of the companys stock, valued at approximately $79,000. Squarepoint Ops LLC owned approximately 0.05% of Aquestive 
Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? 2021/11/25 12:30:00 Marketing Sentinel
During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 0.6 million, with the beta value of the company hitting 3.51. At the end of the trading day, the stocks price was $6.24, reflecting an intraday gain of 4.17% or $0.25. The 52-week high for the AQST share is $8.06, that puts it down Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? Read More »
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Expected to Post Earnings of -$0.37 Per Share 2021/11/24 17:10:42 Transcript Daily
Brokerages expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST) will report earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which 
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Increase in Short Interest 2021/11/23 06:24:42 Transcript Daily
Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large increase in short interest in October. As of October 29th, there was short interest totalling 1,480,000 shares, an increase of 22.3% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 495,300 shares, the days-to-cover ratio is currently 3.0 days. Hedge funds have […]
関連キーワード （医薬品 米国株 アクエスティブ・セラピュ―ティクス AQST Aquestive Therapeutics Inc.）